论文部分内容阅读
目的:观察诺和龙治疗2型糖尿病合并动脉粥样硬化的临床疗效。方法:选取2型糖尿病合并动脉粥样硬化患者82例,随机分为观察组42例和对照组40例,在常规治疗的基础上观察组给予诺和龙(瑞格列奈)降糖治疗,对照组给予瑞易灵(格列吡嗪缓释片)治疗,观察比较两组治疗效果。结果:观察组和对照组患者治疗前FBG、2hPBG、HbA1Chs-CRP、IL-6和CIMT比较无明显差异(P>0.05),观察组治疗后2hPBG、HbA1Chs-CRP、IL-6和CIMT较对照组有明显差异(P>0.05),观察组出现轻微低血糖1例,对照组出现轻微低血糖3例。结论:诺和龙具有降低血糖和预防心脑血管疾病的双重作用,适用于2型糖尿病合并动脉粥样硬化患者。
Objective: To observe the clinical efficacy of Novo-Long in treating type 2 diabetes with atherosclerosis. Methods: A total of 82 patients with type 2 diabetes mellitus and atherosclerosis were randomly divided into observation group (n = 42) and control group (n = 40). On the basis of conventional therapy, Novolin (repaglinide) The control group was given Ru Yi Ling (glipizide sustained-release tablets) treatment, observation and treatment of the two groups were compared. Results: There were no significant differences in FBG, 2h PBG, HbA1Chs-CRP, IL-6 and CIMT between the observation group and the control group before treatment (P> 0.05). The levels of PBG, HbA1Chs-CRP, IL- There was a significant difference between the two groups (P> 0.05). In the observation group, 1 case had mild hypoglycemia and 3 cases had slight hypoglycemia in the control group. Conclusion: Novartis has the dual function of reducing blood sugar and preventing cardiovascular and cerebrovascular diseases and is suitable for patients with type 2 diabetes and atherosclerosis.